首页>
中文期刊>
《海南医科大学学报（英文版）》
>Effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma
Effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma
Objective:To study the effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma. Methods: 138 patients diagnosed with bronchial asthma in our hospital between August 2014 and February 2016 were selected and randomly divided into two groups (n=69), observation group received oral montelukast combined with symbicort inhalation treatment, and control group received symbicort inhalation treatment. 3 months and 6 months after treatment, spirometer was used to measure the airway function parameters, and enzyme-linked immunosorbent assay kits were used to determine Th1/Th2, Treg/Th17 and Th9/cTfh cytokine content. Results:3 months and 6 months after treatment, 1 second (FEV1)/forced vital capacity (FVC), tidal expiratory flow at 25%, 50%and 75%of tidal volume (TEF25%, TEF50%and TEF75%) of observation group were significantly higher than those of control group (P<0.05); serum interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor (TNF-α), IL-10 and transforming growth factor (TGF-β) levels of observation group were significantly higher than those of control group (P<0.05) while IL-4, IL-6, IL-17, IL-22, IL-9 and IL-21 levels were significantly lower than those of control group (P<0.05). Conclusions:Montelukast combined with conventional inhalation treatment of bronchial asthma can more effectively improve the airway function and inhibit the airway inflammatory response mediated by Th1/Th2, Treg/Th17 and Th9/cTfh imbalance.
展开▼
